11/22/2022

SynRx Therapeutics raises over RMB 100 million in Series Pre-A round financing
SynRx Therapeutics has completed a Series Pre-A financing round, raising over RMB 100 million. The round was invested by Lapam Capital, Fenghua Venture, Westlake Innovation Capital and Long Yield Venture Capital.
The company focuses on DNA damage repair pathways and uses synthetic lethality strategies to develop anti-cancer agents.